Cemsidomide (CFT7455) +/- dexamethasone

12/8/24- Updated r/r MM & r/r NHL DE data at ASH'24. 5/7/25- DE phase completed. 9/20/25- Ph1 DE data in MM presented at IMS. Align with FDA on RP2D for Ph2 trial by YE 2025. Initiate Ph2 trial in Q1 2026. 11/06/25:- Ph1 MM data showed 53% ORR at 100 µg. MOMENTUM Ph2 Q1 2026, Ph1b elranatamab Q2 2026. 02/23/26:- First MOMENTUM Ph2 patient dosed. Ph1b elranatamab starts Q2 2026. Ph1 analysis Mid-2026. Ph2 enrollment Q1 2027. 02/26/26:- MOMENTUM Ph2 enrolling; Ph1 analysis Mid-2026; Ph1b elranatamab Q2 2026; additional Ph1b combos Mid-2026. 03/25/26:- First patient dosed in Ph1b elranatamab combo (NCT07280013). Ph1b data expected Mid-2027. Other combo plans Mid-2026. 05/12/26:- Ph1 MM data at EHA June 12 2026. Ph1b elranatamab update 2H 2026. MOMENTUM enrollment completes Q1 2027. 06/11/26:- EHA 2026 poster June 12 shows deeper responses and MRD negativity in Ph1 RRMM.